Hermetica Superfood Encyclopedia
The Short Answer
Manzamine A is a β-carboline-fused polycyclic alkaloid that exerts antimalarial, antimicrobial, and antileishmanial effects primarily through inhibition of serine/threonine kinases including GSK-3β, CDK5, and RSK1, alongside disruption of parasite membrane integrity. In preclinical assays, it cleared Plasmodium falciparum with an IC₅₀ of 19.5 ng/mL against the chloroquine-sensitive D6 strain and 22.0 ng/mL against the resistant W2 strain, and inhibited Mycobacterium intracellulare at an MIC of 0.48 µg/mL, representing potency comparable to or exceeding several reference antimicrobials.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordmanzamine A marine sponge
Manzamine A — botanical close-up
Health Benefits
**Antimalarial Activity**
Manzamine A inhibits both chloroquine-sensitive (D6, IC₅₀ 19.5 ng/mL) and chloroquine-resistant (W2, IC₅₀ 22.0 ng/mL) strains of Plasmodium falciparum, suggesting a mechanism distinct from quinoline-based drugs and potential utility against drug-resistant malaria.
**Antimycobacterial Effects**
The compound inhibits Mycobacterium intracellulare growth at an MIC of 0.48 µg/mL in vitro, a concentration clinically relevant for intracellular mycobacterial infections, though no in vivo or human data exist to confirm this effect.
**Antileishmanial Properties**
Manzamine A demonstrates activity against Leishmania donovani promastigotes in cell-based assays, positioning it as a candidate scaffold for neglected tropical disease drug development pending further mechanistic characterization.
**Kinase Inhibition and Anticancer Potential**
By inhibiting RSK1 kinase as well as CDK5 and GSK-3β, manzamine A sensitizes cancer cell lines to TRAIL-induced apoptosis and may impede metastatic signaling cascades, as demonstrated across human tumor cell panels in preclinical screens.
**Lipid-Lowering and Atheroprotective Effects**
Preclinical in vivo studies report suppression of hyperlipidemia and attenuation of atherosclerotic markers following manzamine A administration, though the precise molecular pathway—whether via HMG-CoA reductase modulation, LDL receptor upregulation, or another route—has not been fully delineated.
**Antibacterial Activity Against MRSA**
Manzamine A displays inhibitory activity against methicillin-resistant Staphylococcus aureus (MRSA) in vitro, underscoring its broad-spectrum antimicrobial profile and relevance to antibiotic-resistant infection research.
**Neuroprotective Kinase Modulation**
Inhibition of GSK-3β and CDK5—both implicated in tau hyperphosphorylation and neurodegeneration—raises hypotheses about manzamine A's relevance to Alzheimer's disease models, though no dedicated neuroprotection studies have been published to date.
Origin & History
Natural habitat
Manzamine A is a complex polycyclic alkaloid first isolated from the marine sponge Acanthostrongylophora ingens, collected from reef environments in Papua New Guinea and Indonesia. The sponge inhabits tropical Indo-Pacific shallow-water and deep-water reef systems, where it harbors symbiotic bacteria—particularly Micromonospora sp.—that are now believed to be the true biosynthetic producers of manzamine alkaloids. There is no agricultural cultivation; all research material is obtained via wild collection and bioassay-guided laboratory extraction.
“Manzamine A has no documented history of traditional or indigenous medicinal use; it was first characterized through modern natural products chemistry and pharmacognosy rather than ethnobotanical investigation. The compound was discovered during systematic bioactivity-guided screening of marine invertebrates collected from Papua New Guinean and Indonesian reef habitats as part of late-twentieth-century marine biodiscovery programs. Indigenous coastal communities in these regions utilized marine organisms for food and in some cases spiritual practices, but there is no recorded use of Acanthostrongylophora ingens sponge as a medicinal preparation in any traditional medicine system. Its entire history is therefore confined to the scientific literature, beginning with its structural elucidation and progressing through contemporary antimalarial and anticancer drug discovery pipelines.”Traditional Medicine
Scientific Research
All available evidence for manzamine A derives exclusively from in vitro bioassays and limited preclinical animal studies; no human clinical trials have been registered or completed as of the most recent literature review. Antimalarial potency (IC₅₀ 19.5–22.0 ng/mL) and antimycobacterial activity (MIC 0.48 µg/mL) were established through standardized cell-based and broth microdilution assays against defined reference strains, providing reproducible but non-clinical data points. Anticancer activity was assessed across the National Cancer Institute's human tumor cell panel, with cytotoxic IC₅₀ values reported for multiple cell lines, though these values do not translate directly to therapeutic doses or tumor selectivity in vivo. The body of evidence is limited in volume, lacks pharmacokinetic characterization in mammals, and relies on isolated compound bioassays rather than formulated interventions, placing manzamine A firmly in the early drug-discovery phase with no established clinical translation.
Preparation & Dosage
Traditional preparation
**Research Extraction Form**
Manzamine A is isolated as a free base or hydrochloride salt via bioassay-guided fractionation of acetone or methanol sponge extracts over alumina (CHCl₃-MeOH-NH₃·H₂O gradient) or silica gel chromatography; not available in commercial supplement form.
**Laboratory Salt Conversion**
The free base is converted to the hydrochloride salt by dissolution in dilute HCl and lyophilization for improved aqueous solubility in bioassays; no oral formulation has been developed.
**Preclinical Effective Concentrations**
In vitro antimalarial activity established at 19.5–22.0 ng/mL; antimycobacterial MIC at 0.48 µg/mL; no in vivo effective dose (ED₅₀) in a mammalian pharmacokinetic model has been published.
**No Human Dose Established**
There is no recommended or investigational human dose; no pharmacokinetic parameters (Cmax, t½, bioavailability) have been reported in any species.
**Timing and Standardization**
No standardization percentage, dosing interval, or formulation guidance exists; use outside controlled research settings is not supported by available data.
Nutritional Profile
Manzamine A is a pure isolated alkaloid compound, not a food or nutritional ingredient, and possesses no macronutrient, micronutrient, or dietary fiber content relevant to human nutrition. It is a nitrogen-containing polycyclic molecule with a molecular formula of C₄₀H₄₅N₅O and a molecular weight of approximately 649 Da, characterized by a β-carboline ring system fused with a large carbocyclic framework. Bioavailability data in any biological system are absent from the published literature; aqueous solubility of the free base is low, while the hydrochloride salt exhibits improved but unquantified solubility. As a research isolate present in sponge tissue at trace concentrations accessible only via multi-step chromatographic purification, it does not contribute meaningfully to any nutritional matrix.
How It Works
Mechanism of Action
Manzamine A acts through multi-target kinase inhibition, most notably suppressing the serine/threonine kinases GSK-3β and CDK5, which regulate cell cycle progression, tau phosphorylation, and inflammatory signaling, as well as RSK1 (ribosomal S6 kinase 1), a downstream effector of the MAPK/ERK pathway involved in cell survival and proliferation. In Plasmodium falciparum, the compound is believed to disrupt intraerythrocytic parasite development through mechanisms that differ from classical quinoline drugs, contributing to its activity against chloroquine-resistant strains, though the precise parasite molecular target remains unconfirmed. Manzamine A sensitizes tumor cells to TRAIL (TNF-related apoptosis-inducing ligand)-mediated apoptosis, suggesting modulation of pro-survival signaling nodes downstream of kinase pathways. Additionally, its in vivo lipid-lowering effect implies interaction with hepatic lipid metabolism regulators, but specific receptor binding constants, gene expression changes, or pathway flux data have not been published.
Clinical Evidence
There are no clinical trials—Phase I, II, or III—involving manzamine A in human subjects. The totality of published human-relevant data consists of in vitro IC₅₀ and MIC determinations, cytotoxicity profiling against tumor cell lines, and at least one preclinical in vivo model demonstrating lipid and atherosclerosis suppression without reported pharmacokinetic endpoints. No effect sizes, confidence intervals, or patient-level outcomes have been generated. Confidence in any therapeutic claim for human use is therefore extremely low, and the compound must be regarded as a research-stage molecule rather than a clinically validated therapeutic or supplement ingredient.
Safety & Interactions
Manzamine A is cytotoxic against multiple human tumor cell lines at concentrations measured in preclinical panels, raising concerns about a potentially narrow therapeutic index if ever advanced to human studies. No formal toxicology studies—acute, subacute, or chronic—in mammalian models have been published, and no maximum tolerated dose, LD₅₀, or no-observed-adverse-effect level (NOAEL) has been established in any species. There are no documented drug interactions, contraindications, or pregnancy and lactation safety data, as the compound has never been administered to humans in any clinical or investigational context. Given its cytotoxic profile, lack of pharmacokinetic data, and complete absence of human safety studies, manzamine A should not be self-administered or used outside controlled laboratory or authorized investigational settings.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
MZASponge Manzamine A (Acanthostrongylophora ingens)Acanthostrongylophora ingens alkaloidManzamine A hydrochlorideβ-carboline marine alkaloidManramian A (misspelling)
Frequently Asked Questions
What is manzamine A and where does it come from?
Manzamine A is a complex polycyclic β-carboline alkaloid isolated from the marine sponge Acanthostrongylophora ingens, collected primarily from Indo-Pacific reef systems in Papua New Guinea and Indonesia. Symbiotic bacteria of the genus Micromonospora found within the sponge tissue are believed to be the actual biosynthetic source of the compound. It is a research-stage molecule with no commercial supplement form.
Does manzamine A have proven benefits for cholesterol or atherosclerosis in humans?
There is currently no human clinical evidence supporting manzamine A as a cholesterol-lowering or atheroprotective treatment; the only relevant data come from preclinical in vivo animal studies that observed suppression of hyperlipidemia and atherosclerotic markers. No clinical trials have been conducted, and no mechanism—such as HMG-CoA reductase inhibition or LDL receptor modulation—has been confirmed in humans. Any cholesterol-related claims remain speculative pending formal pharmacological and clinical investigation.
How does manzamine A work against malaria?
Manzamine A inhibits the growth of Plasmodium falciparum intraerythrocytic stages with IC₅₀ values of 19.5 ng/mL against the chloroquine-sensitive D6 strain and 22.0 ng/mL against the chloroquine-resistant W2 strain in vitro. Its mechanism is believed to differ from quinoline-based antimalarials, potentially involving disruption of parasite kinase signaling or membrane function, though the precise molecular target within the parasite has not been definitively identified. These findings are preclinical only and have not been replicated in human malaria treatment trials.
Is manzamine A safe to take as a supplement?
Manzamine A is not available as a consumer supplement and should not be self-administered; it is an isolated research compound with documented cytotoxicity against human tumor cell lines and no published mammalian toxicology studies establishing a safe dose range. No LD₅₀, NOAEL, or maximum tolerated dose has been reported, and there are no human pharmacokinetic or safety data of any kind. Its use is currently limited to controlled laboratory research environments under appropriate scientific oversight.
What kinases does manzamine A inhibit and why does that matter?
Manzamine A inhibits the serine/threonine kinases GSK-3β (glycogen synthase kinase 3 beta), CDK5 (cyclin-dependent kinase 5), and RSK1 (ribosomal S6 kinase 1) in preclinical assays. GSK-3β and CDK5 are implicated in tau hyperphosphorylation relevant to Alzheimer's disease and in cancer cell survival signaling, while RSK1 is a downstream MAPK/ERK effector that promotes tumor cell proliferation and resistance to apoptosis. These targets make manzamine A of theoretical interest for oncology and neurodegeneration research, but no therapeutic application has been validated in clinical studies.
What is the evidence quality for manzamine A's antimalarial effects compared to standard treatments?
In vitro studies demonstrate that manzamine A inhibits both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum strains with low nanomolar IC₅₀ values (19.5–22.0 ng/mL), suggesting a distinct mechanism from quinoline-based drugs. However, clinical efficacy in humans has not been established, and all current evidence comes from laboratory research rather than human trials. This compound remains a research candidate rather than a proven alternative to FDA-approved antimalarial medications.
Who should consider manzamine A supplementation, and who should avoid it?
Manzamine A is not currently approved as a dietary supplement and lacks adequate safety data for general consumer use, making it unsuitable for self-supplementation by the general population. Individuals with malaria, tuberculosis, or mycobacterial infections might theoretically benefit from further research, but only under medical supervision in a clinical trial setting. Until human safety and efficacy studies are completed, manzamine A should only be used by researchers or patients enrolled in approved clinical studies.
Does manzamine A have activity against antibiotic-resistant bacteria beyond malaria parasites?
Manzamine A demonstrates antimycobacterial activity, inhibiting Mycobacterium intracellulare growth, which suggests potential applications against drug-resistant tuberculosis and related infections. This activity occurs through different biochemical pathways than its antiparasitic effects, indicating the compound has multiple antimicrobial targets. However, efficacy against other antibiotic-resistant bacteria and clinical relevance in humans remain unstudied.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w manzamine-a-acanthostrongylophora-ingens curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
